Latest filing published 09 May 2017 for AtriCure, Inc., €201k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 23 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +45.3%Entry US$7.58 · Close at T+365 US$11.01
- +36.6%Entry US$7.62 · Close at T+365 US$10.41
- +36.6%Entry US$7.62 · Close at T+365 US$10.41
- +37.0%Entry US$7.60 · Close at T+365 US$10.41
- +31.8%Entry US$7.67 · Close at T+365 US$10.11
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Michael D. Hooven: trading record in brief
Michael D. Hooven is a declared insider of AtriCure, Inc., with filings sourced from SEC (Form 4). Between 14 December 2005 and 5 May 2017, the trades on record add up to 51 filings.
Market trades split into 23 purchases (€103k) and 13 sales (€4.3M). Sales outweigh purchases by €4.2M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 share grants and 4 option exercises. 2017 to date brings no purchases and 2 sales.
The median purchase comes to €2,892. After 23 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -11.3%. Past outcomes like these are no guarantee of what comes next.
On 9 May 2017 came the latest disclosure, an open-market sale for €201k in AtriCure, Inc. The most recent open-market purchase was published on 17 September 2012, 5,165 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Michael D. Hooven
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 shares@ US$22.0869.9% of flowCommon StockSEC:0001209191-17-030990:0
- 10,000 shares@ US$9.5030.1% of flowCommon StockSEC:0001209191-17-030990:1
- 3,500 shares@ US$10.02Common StockSEC:0001209191-17-013836:0
- 42,500 shares@ US$21.01Common StockSEC:0001209191-15-030993:0
- 10,000 shares@ US$20.51Common StockSEC:0001209191-15-030993:2
- 18,634 shares@ US$20.50Common StockSEC:0001209191-15-030993:4
- 28,866 shares@ US$20.00Common StockSEC:0001209191-15-000221:0
- 500 shares@ US$7.65Common StockSEC:0001181431-12-050692:0Canonical exit: 13 Dec 2012 (T+90)
- 200 shares@ US$7.67Common StockSEC:0001181431-12-050692:1Canonical exit: 13 Dec 2012 (T+90)
- 340 shares@ US$7.75Common StockSEC:0001181431-12-050692:2Canonical exit: 13 Dec 2012 (T+90)
- 5 shares@ US$7.73Common StockSEC:0001181431-12-050692:3Canonical exit: 13 Dec 2012 (T+90)
- 410 shares@ US$7.36Common StockSEC:0001181431-12-050477:0Canonical exit: 12 Dec 2012 (T+90)
- 700 shares@ US$7.37Common StockSEC:0001181431-12-050477:1Canonical exit: 12 Dec 2012 (T+90)
- 1,150 shares@ US$7.10Common StockSEC:0001181431-12-050270:0Canonical exit: 11 Dec 2012 (T+90)
- 100 shares@ US$7.14Common StockSEC:0001181431-12-050013:0Canonical exit: 10 Dec 2012 (T+90)
- 301 shares@ US$7.15Common StockSEC:0001181431-12-050013:1Canonical exit: 10 Dec 2012 (T+90)
- 744 shares@ US$7.20Common StockSEC:0001181431-12-050013:2Canonical exit: 10 Dec 2012 (T+90)
- 1,015 shares@ US$7.15Common StockSEC:0001181431-12-049846:0Canonical exit: 9 Dec 2012 (T+90)
- 200 shares@ US$7.13Common StockSEC:0001181431-12-049846:1Canonical exit: 9 Dec 2012 (T+90)
- 1,215 shares@ US$6.88Common StockSEC:0001181431-12-049291:0Canonical exit: 6 Dec 2012 (T+90)
- 429 shares0Common StockSEC:0001181431-10-055161:0
- 429 shares0Common StockSEC:0001181431-10-055161:1
- 8,479 shares@ US$8.10Common StockSEC:0001181431-10-055161:2
- 8,157 shares@ US$8.10Common StockSEC:0001181431-10-055161:3
- 692 shares0Common StockSEC:0001181431-09-053197:0
25 of 46 declarations
